Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: Final results of a pilot phase II study

Massimo Federico, Stefano Luminari, Cinzia Pellegrini, Francesco Merli, Emanuela Anna Pesce, Stephane Chauvie, Letizia Gandolfi, Isabella Capodanno, Massimiliano Salati, Lisa Argnani, Pier Luigi Zinzani

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)e139-e141
Number of pages3
JournalHaematologica
Volume101
Issue number4
DOIs
Publication statusPublished - Mar 31 2016

Keywords

  • ABVD
  • Brentuximab vedotin
  • Early
  • Hodgkin lymphoma
  • Intermediate
  • Radiotherapy
  • Toxicity

ASJC Scopus subject areas

  • Hematology

Cite this

Federico, M., Luminari, S., Pellegrini, C., Merli, F., Pesce, E. A., Chauvie, S., Gandolfi, L., Capodanno, I., Salati, M., Argnani, L., & Zinzani, P. L. (2016). Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: Final results of a pilot phase II study. Haematologica, 101(4), e139-e141. https://doi.org/10.3324/haematol.2015.138388